Literature DB >> 27419662

Treatment and Survival of Medicare Beneficiaries with Colorectal Cancer: A Comparative Analysis Between a Rural State Cancer Registry and National Data.

Pallavi B Rane1, S Suresh Madhavan2, Usha Sambamoorthi2, Kalidindi Sita2, Sobha Kurian3, Xiaoyun Pan4.   

Abstract

The aim was to examine and compare with "national" estimates, receipt of colorectal cancer (CRC) treatment in the initial phase of care and survival following a CRC diagnosis in rural Medicare beneficiaries. A retrospective study was conducted on fee-for-service Medicare beneficiaries diagnosed with CRC in 2003-2006, identified from West Virginia Cancer Registry (WVCR)-Medicare linked database (N = 2119). A comparative cohort was identified from Surveillance, Epidemiology, and End Results (SEER)-Medicare (N = 38,168). CRC treatment received was ascertained from beneficiaries' Medicare claims in the 12 months post CRC diagnosis or until death, whichever happened first. Receipt of minimally appropriate CRC treatment (MACT) was defined using recommended CRC treatment guidelines. All-cause and CRC-specific mortality in the 36-month period post CRC diagnosis were examined. Differences in usage of CRC surgery, chemotherapy, and radiation were observed between the 2 populations, with those from WVCR-Medicare being less likely to receive any type of CRC surgery (adjusted odds ratio [AOR] = 0.82; 95% confidence interval [CI] = [0.73-0.93]). Overall, those from WVCR-Medicare had a lower likelihood of receiving MACT, (AOR = 0.85; 95% CI = [0.76-0.96]) compared to their national counterparts. Higher hazard of CRC mortality was observed in the WVCR-Medicare cohort (adjusted hazard ratio = 1.26; 95% CI = [1.20-1.32]) compared to the SEER-Medicare cohort. Although more beneficiaries from WVCR-Medicare were diagnosed in early-stage CRC compared to their SEER-Medicare counterparts, they had a lower likelihood of receiving MACT and a higher hazard of CRC mortality. This study highlights the need for an increased focus on improving access to care at every phase of the CRC care continuum, especially for those from rural settings.

Entities:  

Mesh:

Year:  2016        PMID: 27419662      PMCID: PMC5278801          DOI: 10.1089/pop.2015.0156

Source DB:  PubMed          Journal:  Popul Health Manag        ISSN: 1942-7891            Impact factor:   2.459


  20 in total

1.  Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population.

Authors:  Joan L Warren; Carrie N Klabunde; Deborah Schrag; Peter B Bach; Gerald F Riley
Journal:  Med Care       Date:  2002-08       Impact factor: 2.983

2.  Association of area sociodemographic characteristics and capacity for treatment with disparities in colorectal cancer care and mortality.

Authors:  Jennifer S Haas; Phyllis Brawarsky; Aarthi Iyer; Garrett M Fitzmaurice; Bridget A Neville; Craig Earle
Journal:  Cancer       Date:  2011-03-16       Impact factor: 6.860

3.  Patterns of care for adjuvant therapy in a random population-based sample of patients diagnosed with colorectal cancer.

Authors:  Deirdre P Cronin; Linda C Harlan; Arnold L Potosky; Limin X Clegg; Jennifer L Stevens; Margaret M Mooney
Journal:  Am J Gastroenterol       Date:  2006-10       Impact factor: 10.864

Review 4.  Rates and predictors of chemotherapy use for stage III colon cancer: a systematic review.

Authors:  David A Etzioni; Anthony B El-Khoueiry; Robert W Beart
Journal:  Cancer       Date:  2008-12-15       Impact factor: 6.860

5.  Factors associated with improved survival among older colorectal cancer patients in the US: a population-based analysis.

Authors:  Kathleen Lang; Jonathan R Korn; David W Lee; Lisa M Lines; Craig C Earle; Joseph Menzin
Journal:  BMC Cancer       Date:  2009-07-13       Impact factor: 4.430

6.  Are we undertreating rectal cancer in the elderly? An epidemiologic study.

Authors:  George J Chang; John M Skibber; Barry W Feig; Miguel Rodriguez-Bigas
Journal:  Ann Surg       Date:  2007-08       Impact factor: 12.969

7.  A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients.

Authors:  Carrie N Klabunde; Julie M Legler; Joan L Warren; Laura-Mae Baldwin; Deborah Schrag
Journal:  Ann Epidemiol       Date:  2007-05-25       Impact factor: 3.797

8.  Complementary and alternative medicine use among cancer patients at the end of life: Korean national study.

Authors:  Jin Young Choi; Yoon Jung Chang; Young Seon Hong; Dae Seog Heo; Samyong Kim; Jung Lim Lee; Jong Soo Choi; Ki Mun Kang; Si-Young Kim; Hyun Sik Jeong; Chang Geol Lee; Youn Seon Choi; Ho-Yeong Lim; Young Ho Yun
Journal:  Asian Pac J Cancer Prev       Date:  2012

9.  Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis.

Authors:  G F Riley; A L Potosky; J D Lubitz; L G Kessler
Journal:  Med Care       Date:  1995-08       Impact factor: 2.983

10.  Access to cancer services for rural colorectal cancer patients.

Authors:  Laura-Mae Baldwin; Yong Cai; Eric H Larson; Sharon A Dobie; George E Wright; David C Goodman; Barbara Matthews; L Gary Hart
Journal:  J Rural Health       Date:  2008       Impact factor: 4.333

View more
  2 in total

1.  Post-treatment surveillance testing of patients with colorectal cancer and the association with survival: protocol for a retrospective cohort study of the Surveillance, Epidemiology, and End Results (SEER)-Medicare database.

Authors:  Robert B Hines; Md Jibanul Haque Jiban; Kanak Choudhury; Victoria Loerzel; Adrian V Specogna; Steven P Troy; Shunpu Zhang
Journal:  BMJ Open       Date:  2018-04-28       Impact factor: 2.692

2.  Racial/ethnic disparities in colorectal cancer treatment utilization and phase-specific costs, 2000-2014.

Authors:  Angela C Tramontano; Yufan Chen; Tina R Watson; Andrew Eckel; Chin Hur; Chung Yin Kong
Journal:  PLoS One       Date:  2020-04-14       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.